Clinical trials
Diabetes (Insulin-requiring, Type 1 or Type 2) clinical trials
Below are recruiting diabetes (insulin-requiring, type 1 or type 2) clinical trials, each written for real people, not researchers. We’re tracking 2,190 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07498335RecruitingPhase 3
Atrasentan for children with IgA nephropathy
This trial tests an experimental medicine called atrasentan for children aged 2 to under 18 with IgA nephropathy, a kidney disease. The study aims to see if the drug can help protect kidney function and reduce protein in the urine, with fewer side effects than current treatments.
Neptune City, New JerseyAges 2–18 - NCT06440330Recruiting
Predicting diabetes after kidney transplant study
This study looks for factors that may help predict who will develop diabetes after a kidney transplant. It is for people who have not had diabetes before their transplant and are starting on tacrolimus and steroids.
Edegem, AntwerpenAges 18 years+ - NCT05369052RecruitingPhase 3
New antibiotic for moderate or severe diabetic foot infections
This Phase 3 trial tests a new medicine (contezolid acefosamil, and contezolid) to treat moderate or severe diabetic foot infections. It compares the new treatment to linezolid to see which works better and is safer for adults.
Corona, CaliforniaAges 18 years+ - NCT06874907Recruiting
Predicting gestational diabetes with a glucose monitor in early pregnancy
This study tests whether wearing a continuous glucose monitor (a small sensor on your skin) in early pregnancy can help predict if you will develop gestational diabetes later. The goal is to catch it early so you and your baby get the best care possible.
El Palmar, MurciaAges 18 years+ - NCT06817265RecruitingPhase 3
TNTL for diabetic eye disease (non-proliferative)
This study tests if a drug called TNTL can help people with type 2 diabetes who have early-stage diabetic eye disease (non-proliferative diabetic retinopathy) without severe vision loss. It aims to see if the treatment is safe and effective in slowing or improving the condition.
Xuancheng, AnhuiAges 18–75 - NCT06783114RecruitingPhase 2/Phase 3
Testing a new Botox-like injection for arm stiffness after stroke
This study tests an investigational botulinum toxin injection (YY001) to reduce muscle stiffness in the arm after a stroke. It may help you move your arm more easily and improve daily tasks.
Hefei, AnhuiAges 18–75 - NCT06619860RecruitingPhase 2
VX-993 for diabetic nerve pain
This trial tests a new medicine called VX-993 for people with diabetes who have had nerve pain in both feet or legs for at least a year. The goal is to see if it reduces pain and is safe.
Cullman, AlabamaAges 18–80 - NCT06412224RecruitingEarly Phase 1
Testing a new drug for diabetic eye disease after vitrectomy
This trial tests a new medicine, RRG001, given after vitrectomy surgery for severe diabetic eye disease. It aims to see if the drug is safe and helps prevent vision loss.
TianjinAges 20–80 - NCT06258863Enrolling by invitation
Comparing incision types in breast reconstruction after mastectomy
This study compares different types of surgical cuts (incisions) used during breast reconstruction after mastectomy. It looks at which incision gives the best cosmetic result and causes the fewest problems. Researchers want to find out which technique is best for you.
Wuhan, Hongshan DistrictAges 18 years+ - NCT05656105RecruitingEarly Phase 1
PET scan study of brain inflammation after COVID
This early-phase study uses a special PET scan to look for signs of brain inflammation in people with ongoing (long-term) nervous system symptoms after COVID-19. It may help researchers understand what is driving symptoms and whether this imaging approach can detect inflammation.
Birmingham, AlabamaAges 18–65 - NCT05229224Recruiting
Study of a new device for frequent tension headaches
This pilot study tests a device approach (“Osteo-Fluidic-Sensitive”) for people who get frequent episodic tension-type headaches. It aims to see whether the device is safe and can reduce headache burden for the right kind of headache pattern.
PoitiersAges 18–75 - NCT02622542Recruiting
Stent repair versus best medical care for type B dissection
This trial compares an endovascular stent (placed through blood vessels) to best medical therapy (blood pressure and pain control) for certain “uncomplicated” type B aortic dissections. It aims to see which approach works better in the early period after symptoms start.
Houston, TexasAges 18 years+ - NCT04991831Recruiting
Registry study for Exablate thalamotomy in tremor-dominant Parkinson’s
This study follows people who are getting an Exablate procedure to treat medication-resistant, tremor-dominant Parkinson’s. It aims to track safety and outcomes in real-world care after the treatment is approved.
Miami, FloridaAges 30–99 - NCT06821100RecruitingPhase 1
Thymalfasin to Boost COVID-19 Vaccine Response in Older Adults
This trial tests whether a drug called thymalfasin (thymosin alpha 1) can help older adults (65+) get a stronger immune response from their COVID-19 booster shot. It may be especially helpful for those whose immune systems have weakened with age.
Houston, TexasAges 65–100 - NCT06217861RecruitingPhase 1
Gene therapy for children with GA-1 not helped by standard care
This trial tests a new gene therapy (VGM-R02b) for children with Glutaric Acidemia Type 1 (GA-1) whose symptoms are not well controlled by standard treatment. The goal is to see if the therapy is safe and can help improve neurological symptoms.
Hangzhou, ZhejiangAges Up to 6 years - NCT05728476Recruiting
Compare eye surgery plus peeling versus anti-VEGF injections
This trial compares a minimally invasive eye procedure (vitrectomy with peeling) versus anti-VEGF injections to treat new diabetic macular edema in people who have not had treatment yet. It looks at which option improves vision and eye swelling for people with diabetes.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07605520RecruitingEarly Phase 1
COVID-19 Booster Vaccine Study for Previously Vaccinated Adults
This study tests new COVID-19 booster vaccine candidates in healthy adults who previously received mRNA COVID-19 vaccines. Researchers will monitor safety and how well your immune system responds to help develop better COVID-19 protection.
CréteilAges 18–65 - NCT07515079RecruitingPhase 3
Testing BAT5906 vs Lucentis for diabetic vision swelling
This study compares two injectable medicines (BAT5906 and Lucentis) to treat diabetic macular edema—swelling in the back of the eye that blurs vision. Both drugs block a protein that causes abnormal blood vessel leakage, and this trial will show which works better.
Beijing, Beijing MunicipalityAges 18–80 - NCT07717554Recruiting
Virtual yoga for diabetic stomach-pain relief
This study tests if virtual yoga classes can help people with diabetes and gastroparesis (slow stomach emptying) feel better. It looks at whether yoga can ease symptoms like nausea, bloating, and stomach pain.
Columbus, OhioAges 18–65 - NCT05973552Recruiting
Study iron absorption in early pregnancy and breastfeeding
This study looks at how your body absorbs iron during early pregnancy and after birth. The results may help researchers understand iron needs and how iron levels change, which could support healthier pregnancy and breastfeeding outcomes.
MsambweniAges 18–45 - NCT07458061RecruitingPhase 1/Phase 2
Kamuvudine-9 for diabetic macular edema
This trial tests a new drug, Kamuvudine-9 (K9), to treat diabetic macular edema (swelling in the back of the eye caused by diabetes). It may help improve vision in people with diabetes who have not yet needed major treatments.
Roanoke, VirginiaAges 18 years+ - NCT06556199RecruitingPhase 1/Phase 2
Study of selinexor combo for returning brain lymphoma
This trial tests a new combination of drugs (selinexor, temozolomide, and an immunotherapy) for people whose primary central nervous system lymphoma has come back or stopped responding to previous treatment. The goal is to see if this combination can help shrink or control the lymphoma.
Hanzhou, ZhejiangAges 18–75 - NCT06735755RecruitingPhase 1/Phase 2
Study of BEAM-301 for glycogen storage disease type Ia
This study tests an experimental medicine called BEAM-301 for people with a specific form of glycogen storage disease type Ia (GSDIa). The goal is to see if it can help reduce dangerous low blood sugar episodes.
Orange, CaliforniaAges 18 years+ - NCT06979037Recruiting
Genetics of diabetic ulcers and personalized treatment
This study looks for genetic markers in people with type 2 diabetes and diabetic ulcers to help find better, personalized treatments. If you join, researchers will track your health to understand which treatments work best for your specific needs.
Hengyang, HunanAges 18 years+
Hear when a new Diabetes (Insulin-requiring, Type 1 or Type 2) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for diabetes (insulin-requiring, type 1 or type 2)?
- Yes. Clin2 currently lists 2,190 recruiting diabetes (insulin-requiring, type 1 or type 2) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a diabetes (insulin-requiring, type 1 or type 2) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a diabetes (insulin-requiring, type 1 or type 2) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.